Home
Live Updates
Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU : comparemela.com
Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU
/PRNewswire/ -- Johnson & Johnson announced today new clinical and real-world evidence data will be featured in 18 abstracts at this year's ASCO GU Symposium...
Related Keywords
Japan ,
San Francisco ,
California ,
United States ,
Japanese ,
Luca Dezzani ,
Obrian Kenney ,
Kiran Patel ,
Laboratory Abnormalities ,
Exchange Commission ,
York Heart Association ,
Janssen Research Development ,
Astex Pharmaceuticals ,
Janssen Pharmaceuticals ,
Clinical Development ,
None Of Janssen Research Development ,
Early Development ,
Data Monitoring Committee ,
European Medicines Agency ,
Janssen Biotech Inc ,
Johnson ,
Janssen Scientific Affairs ,
Vice President ,
Solid Tumors ,
Johnson Innovative ,
Medical Affairs ,
Bacillus Calmette Gu ,
Breakthrough Therapy Designation ,
Acute Myeloid Leukemia ,
Fluid Retention ,
Cardiovascular Adverse Reactions ,
Torsades De Pointes ,
New York Heart Association ,
Independent Data Monitoring Committee ,
Reversible Encephalopathy Syndrome ,
Posterior Reversible Encephalopathy Syndrome ,
Fetal Toxicity ,
Prescribing Information ,
Ischemic Cardiovascular Events ,
Cutaneous Adverse Reactions ,
All Grades ,
Soft Tissue Mineralization ,
Embryo Fetal Toxicity ,
Innovative Medicine ,
Janssen Research ,
Janssen Biotech ,
Private Securities Litigation Reform Act ,
Annual Report ,
Note Regarding Forward Looking ,
Quarterly Reports ,
Participants With Advanced Solid Tumors ,
Fibroblast Growth Factor Receptor ,
Accessed May ,
Johnson Amp ,
comparemela.com © 2020. All Rights Reserved.